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APAAP = alkaline phosphatase anti-alkaline phosphatase; CD = cluster of differentiation; DMEM = Dulbecco’s modified Eagle medium; FACS =
flow cytometry; FCS = fetal calf serum; FITC = fluoresceine isothiocyanate; HUVEC = human umbilical vein endothelial cells; mAb(s) = monoclonal
antibody(ies); MFI = mean fluorescence intensity; MHC = major histocompatibility complex; NK = natural killer; OA = osteoarthritis; PBS = phos-
phate-buffered saline; PDGF = platelet-derived growth factor; RA = rheumatoid arthritis; SFB = synovial fibroblasts; SM = synovial membrane; TBS
= Tris-buffered saline; VCAM-1 = vascular cell adhesion molecule-1.
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Abstract
To reduce culture artifacts by conventional repeated passaging and long-term culture in vitro, the
isolation of synovial fibroblasts (SFB) was attempted from rheumatoid arthritis (RA) synovial
membranes by trypsin/collagenase digest, short-term in vitro adherence (7 days), and negative
isolation using magnetobead-coupled anti-CD14 monoclonal antibodies. This method yielded highly
enriched SFB (85% prolyl-4-hydroxylase+/74% Thy-1/CD90+ cells; <2% contaminating macrophages;
<1% leukocytes/endothelial cells) that, in comparison with conventional fourth-passage RA-SFB,
showed a markedly different phenotype and significantly lower proliferation rates upon stimulation with
platelet-derived growth factor and IL-1b. This isolation method is simple and reliable, and may yield
cells with features closer to the in vivo configuration of RA-SFB by avoiding extended in vitro culture.
Keywords: isolation, phenotype/function, primary culture, rheumatoid arthritis, synovial fibroblasts
Synopsis
Introduction: Activated SFB in the invasive pannus tissue appear
to play a major role in the crippling destruction of cartilage and
bone in the joints of patients with RA [1–3]. Several studies
indicate that RA-SFB are morphologically altered [1,4], grow in an
anchorage-independent fashion [5], and strongly express markers
of activation, including major histocompatibility complex (MHC)-II
and other surface molecules, proto-oncogenes, or matrix
degrading enzymes (reviewed in [2]). Finally, activated RA-SFB
elicit erosive arthritis upon intra-articular injection or engraftment
into severe combined immunodeficiency mice [6,7].
Aims: To investigate ex vivo the pathophysiological properties of
activated FB from the RA synovial membrane (SM), it is desirable
to obtain freshly isolated SFB with phenotypic features as close
as possible to the configuration observed in vivo. Because the
generation of cell lines requires a number of passages in vitro to
eliminate contaminating cells (especially macrophages), the risk
of substantial in vitro alteration/growth selection exists.
We attempted to isolate FB from primary cultures of synovial
cells, using a negative separation technique to eliminate
macrophages, to minimize these artifacts.Methods: Synovial tissue was obtained from a total of 16
patients fulfilling the American Rheumatism Association
criteria for RA [8] and 21 patients with osteoarthritis (OA)
under approval of the local Ethics Committees. The tissue was
placed in cell culture medium at ambient temperature and
subjected to tissue digestion within 2h. Synovectomy samples
of RA and OA SM were finely minced, digested for 30 min at
37°C in phosphate-buffered saline (PBS) containing 0.1%
trypsin (Sigma, Deisenhofen, Germany), and thereafter
digested in 0.1% collagenase P (Boehringer Mannheim,
Mannheim, Germany) in Dulbecco’s modified Eagle medium
(DMEM)/10% fetal calf serum (FCS) for 2h at 37°C, 5% CO2.
The cell suspension was then filtered and the cells collected
by centrifugation. Cells were kept in primary culture for 7 days
(DMEM/10% FCS, 25mM HEPES, 100U/ml penicillin,
100mg/ml streptomycin, and 2.5mg/ml amphotericin B [Gibco
BRL, Eggenstein, Germany], including removal of non-
adherent cells on days 1, 3, 5, and 7) and subsequently used
for SFB isolation. The samples were randomly tested to
exclude  Mycoplasma contamination. For negative isolation of
SFB from primary culture, adherent synovial cells were
detached by short-term trypsinization for 2 min (0.25%
trypsin/0.2% EDTA; Gibco) and 107/ml synovial cells were
incubated with 4×107/ml Dynabeads® M-450 CD14 (clone
RMO52; Dynal, Hamburg, Germany) in PBS/2% FCS for 1h
at 4°C. Nine milliliters of PBS/2% FCS were then added and
the conjugated cells collected using the Dynal magnetic
particle concentrator®. The compositions of magnetobead-
conjugated cells and unconjugated cells were analyzed by
flow cytometry. Phenotype analysis of the expression of FB
markers, as well as that of SFB features previously reported at
a tissue level, was conducted by flow cytometry in RA-SFB,
either negatively isolated from primary culture or obtained from
conventional fourth passage. The findings were compared
with those of normal skin-FB (lineage control) and OA-SFB
(disease control). The proliferation of RA-SFB, either
negatively isolated from primary culture or obtained from
conventional fourth passage, was assayed by [3H]-thymidine
incorporation.
Results: The primary culture of RA synovial cells resulting from
trypsin/collagenase digestion of the RA SM contained large,
spindle-shaped Thy-1+ SFB (CD90+; Fig. 1C) (monoclonal
antibody [mAb] AS02; Dianova, Hamburg, Germany) and small,
round CD14+ cells, most probably macrophages (Fig. 1D) (mAb
Tyk4; Dako, Hamburg, Germany), as detected by
immunohistochemical staining [6,9]. Endothelial cells were
absent, as confirmed by lack of staining for von Willebrand
Factor (Fig. 1F) (mAb 4F9; Immunotech, Hamburg, Germany)
and CD144 (Fig. 1G) (mAb Cadherin 5; Immunotech), which
clearly identified human umbilical vein endothelial cells (HUVEC)
(data not shown). The FB nature of the spindle-shaped cells was
confirmed by intracellular staining for procollagen I and III
(Fig. 1E,H) (rabbit antibodies MP I and MP III; Prof. Schuppan,
Berlin, Germany). An average of 62% of the cells stained with
the anti-Thy-1 mAb AS02 (n=4 RA patients; Table 1a) in flow
cytometry (FACS) [10]; the average percentage of CD14+ cells
was approximately 15% (n=4; Table 1a). There were <1%
T cells (CD3+) (mAb UCHT-1; ATCC, Manassas, VA, USA),
B cells (CD19+/20+) (mAbs HD 37 and B-Ly 1; Dako), plasma
cells (CD38+) (mAb AT 13/5; Dako), natural killer (NK) cells
(CD56+) (mAb NKH/1; Immunotech), dendritic cells (CD83+)
(mAb HB 15a; Immunotech), endothelial cells (CD144+), or
PMN (CD15+) (mAb 80H5; Immunotech), indicating that non-
adherent cells had been efficiently removed during primary
culture. The total yield of cells following 7 days of primary culture
averaged (5.2±1.1)×107 cells (mean±SEM; n=7).
Negative isolation of SFB from primary culture resulted in
RA-SFB that were Thy-1+ (on average, approximately 74%;
n=9; Fig. 2A and Table 1b) and, more importantly, prolyl-4-
hydroxylase+ (on average, approximately 85%; n=9; Table 1b)
(mAb 3-2B12; Dianova), as shown by FACS analysis and
confirmed by immunohistochemistry in chamber slides. There
were very few contaminating non-specific esterase+ (three RA
patients; Fig. 2C), CD14+, CD68+, and/or CD11b+
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Figure 1
Immunohistochemical staining of primary-culture RA synovial cells in
chamber slides: (A), (B), (D)–(H) phase contrast, and (C) lightfield.
While (A) control isotype-matched mAbs (peroxidase) or (B) rabbit
serum (APAAP) showed no positive reaction, (C) the anti-Thy-1 mAb
AS02 stained large, flat, spindle-shaped or stellate-shaped cells (ie
cells with FB morphology; alkaline phosphatase, purple staining) and
(D) the anti-CD14 mAb RMO52 identified small, round cells,
conceivably macrophages (peroxidase, brown staining). The RA-SFB
clearly expressed (E) procollagen I and (H) procollagen III (APAAP,
red staining). The primary culture contained no endothelial cells, as
documented by the lack of staining for (F) von Willebrand factor
(APAAP) and (G) CD144 (APAAP). Original magnification: (A), (B),
(F), and (G), 184 ×; (C)–(E) and (H) 368 ×.macrophages (<2%; Fig. 2B,D and Table 1b), as well as <1%
T cells (CD3+), B cells (CD19+/20+), plasma cells (CD38+),
NK cells (CD56+), dendritic cells (CD83+), PMN (CD15), or
endothelial cells (CD144+; von Willebrand factor-positive). The
positive fraction, in turn, contained virtually no SFB, indicating
minimal cell loss, and thereby also excluding major subset
selection. The average yield of RA-SFB negatively isolated from
primary culture was (2.8±0.9)×107 cells (mean±SEM; n=7).
Phenotype analyses yielded two main results. The first,
regarding expression of SFB features previously reported at a
tissue level, was that, strikingly, approximately 66% of the cells
expressed MHC-II molecules (normal skin-FB, 2%; OA-SFB,
17%). A low or moderate and variable percentage of RA-SFB,
but also normal skin-FB and OA-SFB, expressed vascular cell
adhesion molecule-1 (VCAM-1) (using two different anti-
VCAM-1 mAbs) without statistically significant differences
between the three different FB preparations. RA-SFB showed
a higher (although non-significant) mean fluorescence intensity
(MFI) for the cytoskeletal protein vimentin than normal skin-FB.
Approximately 45% and 50% of the cells, respectively,
expressed procollagen I and procollagen III (similar to normal
skin-FB); however, the MFI for procollagen III was significantly
higher in RA-SFB. Approximately 57% of RA-SFB expressed
c-Fos. Neither the percentage nor the MFI were significantly
different from those of normal skin-FB (approximately 87%) or
OA-SFB (approximately 54%). In general, the differences
between RA-SFB and normal skin-FB were not specific to RA,
since they were also observed in the comparison between the
disease control OA-SFB and normal skin-FB. The second
outcome of phenotype analysis was that the percentages of
RA-SFB positive for MHC-II as well as the MFI for VCAM-1 and
c-Jun were significantly decreased in conventional fourth
passage compared with isolated primary RA-SFB. In contrast,
the percentages of cells positive for MHC-I, CD13, prolyl-4-
hydroxylase, vimentin, procollagen I and III, c-Fos, and Jun-D
were significantly increased in conventional fourth passage.
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Table 1
Composition of rheumatoid arthritis (RA)-synovial fibroblasts (SFB), osteoarthritis (OA)-SFB, and normal skin-FB, as determined
by flow cytometry for various numbers of patients/donors
Percent of positive cells Mean fluorescence intensity
Composition Mean ± SEM Range Mean ± SEM Range
(a) Primary-culture RA synovial cells
Thy-1 (CD90) (n = 4) 62.0 ± 14.6 24–93 152 ± 49 46–283
CD14 (n = 4) 14.8 ± 6.0 2–25 230 ± 87 64–445
(b) RA-SFB (negative isolation from primary culture; negative fraction)
Thy-1 (n = 9) 73.8 ± 9.6 21–99 109 ± 20 53–222
Prolyl-4-hydroxylase (n = 9) 84.8 ± 2.9 66–95 164 ± 45 20–391
CD14 (n = 9) 0.7 ± 0.2 0.1–1.7 62 ± 12 30–126
CD68 (mAb PG-M1) (n = 5) 1.7 ± 0.6 0.4–3.2 120 ± 78 10–430
(c) RA-SFB (fourth-passage; isolated cells)
Thy-1 (n = 3) 86.6 ± 4.6 79–95 41 ± 7 27–53
Prolyl-4-hydroxylase (n = 3) 98.7 ± 0.8 97–100 164 ± 62 82–285
CD14 (n = 3) 0.6 ± 0.2 0.2–1.0 50 ± 30 20–110
(d) RA-SFB (fourth-passage; conventionally passaged cells)
Thy-1 (n = 6) 85.9 ± 3.9 70–95 95 ± 15 43–167
Prolyl-4-hydroxylase (n = 6) 98.3 ± 0.6 95–99 189 ± 75 20–518
CD14 (n = 6) 1.6 ± 0.6 0.2–4.9 83 ± 32 22–255
CD68 (mAb PG-M1) (n = 3) 0.5 ± 0.0 0.5–0.6 29 ± 6 19–40
(e) OA-SFB (negative isolation from primary culture; negative fraction)
Thy-1 (n = 9) 62.1 ± 9.0 28–92 120 ± 36 53–404
Prolyl-4-hydroxylase (n = 7) 92.2 ± 2.8 77–98 212 ± 44 30–382
CD14 (n = 9) 1.3 ± 0.3 0.7–3.0 268 ± 97 14–754
CD68 (mAb PG-M1) (n = 7) 1.3 ± 0.2 0.6–2.1 58 ± 18 14–140
(f) OA-SFB (fourth-passage; conventionally passaged cells)
Thy-1 (n = 3) 80.9 ± 5.0 72–93 56 ± 6 46–70
Prolyl-4-hydroxylase (n = 3) 98.8 ± 0.3 98–99 250 ± 27 205–313
CD14 (n = 3) 1.0 ± 0.5 0.2–2.2 24 ± 1 22–26
(g) Primary culture or first-passage normal skin-FB
Thy-1 (n = 8) 91.4 ± 3.0 78–99 156 ± 36 34–349
Prolyl-4-hydroxylase (n = 8) 70.7 ± 15.2 2–99 101 ± 31 10–269
CD14 (n = 8) 1.5 ± 0.4 0.3–4.0 70 ± 14 22–130
CD68 (mAb PG-M1) (n = 5) 0.5 ± 0.3 0.1–1.4 82 ± 25 12–164
mAb, Monoclonal antibody.Introduction
Activated SFB play a major role in the crippling destruc-
tion of cartilage and bone in the joints of patients with RA
[1,2,12–15], either autonomously [1] or in concert with
T cells and macrophages [16–19]. RA-SFB are a major
part of the invasive pannus, a vascular and fibrous granula-
tion tissue arising from the joint recessus and extending
onto the surface of cartilage [20]. Several studies indicate
that RA-SFB are morphologically and functionally altered
[4,5,12], and strongly express markers of activation,
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Proliferation assays showed that, at rest, the proliferation rates
of isolated first-passage RA-SFB did not significantly differ
from those of the corresponding cells in conventional fourth
passage. Upon stimulation with platelet-derived growth factor
(PDGF) (2.5 and 5U/ml) and IL-1b (150U/ml), however, the
mean proliferation rates of conventional fourth-passage
RA-SFB were significantly higher than those observed in first-
passage cells (3.9-fold and 4.2-fold, respectively, in the case of
2.5 and 5U/ml PDGF; 2.1-fold in the case of 150U/ml IL-1b).
Discussion: The advantages of negative isolation are as
follows: first, there was minimal contamination with other cells,
especially macrophages (<2%); second, negative isolation
avoided direct contact of SFB with mAbs and/or
magnetobeads, thereby limiting possible functional alterations
of the cells; and third, the FB marker mAb AS02 (anti-Thy-1;
used in the parallel attempt to positively isolate SFB) identified
91% of primary-culture/first-passage normal skin-FB but only
74% of isolated primary RA-SFB, probably due the variable
density of Thy-1 molecules on the cell surface (Table 1). Thus,
Thy-1-independent isolation appears to avoid selection of
Thy-1+ SFB subpopulations, a critical point since Thy-1+ and
Thy-1– FB diverge in several characteristics potentially relevant
to RA.
Potential disadvantages of the negative isolation method
include the limited number of cells obtained (approximately
2.8×10 7), due to the lack of in vitro expansion, and the
necessity for reliable access to freshly obtained synovial
specimens. However, the applicability of this procedure not
only to joint replacement samples, but also to arthroscopic
synovectomy samples, augments the potential sources of fresh
synovial tissue. The use of enzymes for tissue digestion may
also represent at least a transient stress for the cells. On the
other hand, this method may avoid selection of premitotic FB, a
problem usually linked to tissue-outgrowth techniques [11].
The advantages of limited-passage isolation include the
following. The present technique avoids a high number of
passages in vitro; indeed, even a low number of passages
increased the proliferation rates in response to cytokine
stimulation and altered the cellular phenotype of RA-SFB (as
exemplified by a strong decrease of the percentage of MHC-II+
cells, on one hand, and a striking increase of the percentage of
procollagen I and III+, as well as c-Fos and Jun-D+ cells, on the
other). Caution should thus be applied to the interpretation of
data from passaged cells, especially in the case of proto-
oncogenes. A second advantage is that this isolation
procedure reduces the time of exposure (7 days) to surviving
macrophages (unlike the weeks of exposure upon conventional
isolation), thus possibly minimizing long-term in vitro changes
due to monokine secretion or cell–cell contact between SFB
and synovial macrophages. Finally, a high percentage of
RA-SFB from limited-passage isolation expressed MHC-II
molecules (in analogy to findings in synovial tissue) without in
vitro stimulation with cytokines, which in conventionally isolated
cells requires stimulation with interferon-gamma. Therefore, the
present in vitro system may be particularly useful in studies on
the inter-relationship of SFB with T cells or macrophages, in
which the influence of exogenous mediators may complicate
the design and/or interpretation of the experiments.
Negative isolation of cells from synovial primary culture with
magnetobead-conjugated anti-CD14 mAbs thus yielded highly
enriched RA-SFB. This technique, by avoiding repeated
passaging and numerous cumulative population doublings, may
minimize the risk of in vitro alteration/growth selection; in
RA-SFB, this includes increased proliferation rates and
changes of several phenotypic features.
Figure 2
FACS/histochemical analysis of the negative fraction following
isolation of RA-SFB from primary culture using Dynabeads® M-450
CD14. The AS02/Thy-1+ RA-SFB (A) were almost free of
contaminating CD14+ (B) (mAb Tyk4) or CD68+ macrophages (D)
(mAb PG-M1). The RA-SFB were accordingly negative for the
macrophage marker non-specific esterase (histochemistry (C)).
Original magnification: (C) 184 ×. PE, phycoerythrine; FITC,
fluoresceine isothiocyanate.
Full articleincluding surface molecules (eg MHC-II, CD13, or
VCAM-1 and other integrins) [1,2,13,21,22] and proto-
oncogenes [23–25].
Activation of SFB in vitro generates several functional
responses that may considerably contribute to joint
pathology in RA; that is, the production of matrix compo-
nents [11,26], soluble mediators [17,27], or matrix
degrading enzymes [28–30]. Because of the capability to
act as antigen-presenting cells, activated SFB can also
potentially fuel local antigen-driven processes relevant to
the immunopathogenesis of RA [19,31]. Finally, stimu-
lated RA-SFB elicit erosive arthritis upon intra-articular
injection or engraftment into severe combined immuno-
deficiency mice [6,7].
To investigate ex vivo the pathophysiological properties of
activated FB from the RA SM, it is desirable to obtain
freshly isolated SFB with phenotypic features as close as
possible to the configuration observed in vivo. Because the
generation of cell lines requires a number of passages 
in vitro to eliminate contaminating cells (especially
macrophages), the risk of substantial in vitro growth selec-
tion exists [32]. Indeed, increasing the number of passages
modifies the surface phenotype of synoviocytes [19] and
increases the frequency of genotype changes [33]. We
attempted to isolate FB from primary cultures of synovial
cells to minimize these artifacts, with careful characteriza-
tion of each preparation step and comparison of the phe-
notypic and functional features of primary-culture SFB with
those of repeated-passage cells. Both positive and nega-
tive isolation approaches were pursued.
Positive identification/isolation of SFB was attempted
using the mAb AS02, an antibody initially described as
FB-specific [9] and subsequently shown to recognize the
Thy-1 molecule (CD90, highly glycosylated membrane-
bound protein; molecular weight, 30–35 kDa; core protein,
17kDa; anchored via glycosylphosphatidyl-inositol [34]).
Negative isolation was performed using magnetobead-
conjugated anti-CD14 mAbs. The choice of CD14 was
based on the consideration that this is regarded as a reli-
able surface marker for RA synovial macrophages [23,35];
CD14 is also the macrophage marker most clearly corre-
lated with disease activity and radiologic progression of
joint destruction in RA [36]. The use of the most valid
alternative (ie anti-CD68 mAbs) is limited by predominant
expression of the CD68 antigen in the lysosomal compart-
ment (requiring permeabilization of all cells for negative
selection), and by the fact that CD68 epitopes recognized
by certain mAbs are not specific for macrophages, but are
also expressed by SFB [37,38]. The possibility of using
anti-CD11b mAbs was also discarded, because CD11b is
not specific for monocytes/macrophages and is also
found on granulocytes and NK cells. CD11b expression
on subpopulations of RA synovial macrophages may also
be variable [39], possibly due to the local influence of
cytokine stimulation [40,41]. Therefore, although the
expression of CD14 on RA synovial macrophages may
also be influenced by cytokines [36,42,43], the anti-CD14
mAb appeared the most appropriate choice for the
purpose of this study.
Negative isolation from primary culture with magnetobead-
conjugated anti-CD14 mAbs yielded highly enriched
RA-SFB, positive for the known FB marker prolyl-4-hydrox-
ylase (85%) and the recently suggested FB marker Thy-1
(74% [9]), with <2% macrophage contamination and
<1% T cells, B cells, plasma cells, NK cells, dendritic
cells, endothelial cells, or PMN. These cells bore surface
and intracellular characteristics typical of the FB lineage
when compared with primary-culture normal skin-FB
(lineage control) or OA-SFB (disease control).
Materials and methods
Patients
Synovial tissue was obtained during open joint replace-
ment surgery or arthroscopic synovectomy from a total of
16 patients with the clinical diagnosis of RA (13 knee
joints, one hip joint, one wrist, one metacarpo-phalangeal
joint) as well as 21 patients with the clinical diagnosis of
OA (all knee joints; Table 2) from the Department of
Orthopedics, University of Leipzig, Germany, the Clinic
of Orthopedics, Bad Düben, Germany, and the Clinic of
Orthopedics, Eisenberg, Germany, as well as the
Department of Orthopedic Surgery, University of Michi-
gan, Ann Arbor, MI, USA. All RA patients fulfilled the
American Rheumatism Association  criteria for RA [8].
The study was approved by the Ethics Committees of
the University of Leipzig and the University of Jena,
Germany, and the University of Michigan, MI, USA. One
portion of each sample was immediately frozen in
isopentane (Merck, Darmstadt, Germany), cooled in
liquid nitrogen and stored at –70°C for immunohisto-
chemistry. The remaining tissue was placed in cell
culture medium at ambient temperature and subjected to
tissue digestion within 2h.
Histochemical detection of non-specific esterase
Non-specific esterase activity was analyzed in methanol-
fixed (10 min at room temperature) first-passage RA-SFB
and OA-SFB on chamber slides, and in air-dried, unfixed
rat kidney sections or rat peritoneal macrophages, by incu-
bation for 1h at 37°C with a reaction medium containing
0.02% 5-bromo-4-chloro-3-indoxylacetate (initially dis-
solved in dimethylformamide), 1mM potassiumferricyanide,
and 1mM potassiumferrocyanide (final concentrations) (all
from Sigma) in 2mM Tris–HCl buffer (pH 6.8). The posi-
tive controls (rat kidney or peritoneal macrophages) were
stained in all experiments, while negative control cell
preparations/kidney sections incubated with substrate-
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tive data not shown). The cells/sections were then
washed in PBS (see later) and mounted in glycerin gelatin.
Immunohistochemistry
Immunohistochemical analysis was performed on cryostat
sections of RA SM (fixed with acetone for 10 min at 4°C) or
chamber slides (fixed with 100% methanol for 10 min at
room temperature; Nunc, Wiesbaden, Germany) using the
antibodies presented in Table 3. The mouse mAbs, diluted in
Tris-buffered saline (TBS)/1% bovine serum albumin for per-
oxidase/alkaline phosphatase detection, were added for
30 min in a humid chamber at room temperature following
pre-incubation of the sections/chambers with 20% normal
human serum in TBS for 20 min (pH 7.4). A peroxidase-
coupled rabbit anti-mouse antibody (Dako) and a peroxi-
dase-coupled swine anti-rabbit antibody (Dako; both 1:30 in
TBS/20% human serum) were added for 30 min each. The
peroxidase was revealed using diaminobenzidine (5 min,
0.5mg diaminobenzidine in 1ml PBS [pH 7.4] containing
30ml H2O2). Blocking of endogenous peroxidase (0.03%
H2O2) before immunohistochemical analysis, as performed
in some experiments, did not alter the staining results.
Alternatively, either the indirect alkaline phosphatase or the
alkaline phosphatase anti-alkaline phosphatase (APAAP)
techniques were used for detection of the monoclonal or
polyclonal primary antibodies [35]. An alkaline phos-
phatase-coupled goat-anti-mouse antibody (Dako) was
applied for 30 min (1:30 in TBS/20% human serum;
pH 7.4) in the case of the indirect alkaline phosphatase,
and the alkaline phosphatase was revealed in substrate
buffer (TBS; pH 9.5) containing 0.16mg/ml 5-chromo-4-
chloro-3-indoxylphosphate and 0.15mg/ml nitroblue tetra-
zolium chloride (both from Boehringer Mannheim). In the
case of the APAAP, a rabbit anti-mouse antibody (Dako)
was applied for 45 min (1:100 in TBS/20% human serum;
pH 7.4). The sections/chamber slides were washed, incu-
bated for 45 min with APAAP complex (1:80 in TBS/1%
bovine serum albumin; Dianova), and washed again with
TBS. To amplify the staining, incubation with the rabbit anti-
mouse mAb and the APAAP was repeated once. The alka-
line phosphatase was revealed in Tris–HCl buffer (pH 8.6)
containing 0.3mg/ml Naphthol AS-MX phosphate (first dis-
solved at 15mg/ml in dimethylformamide; both from
Sigma), 1mg/ml Fast Red TR salt or Fast Blue BB salt, and
0.24mg/ml levamisole (all from Sigma). The solution was
filtered and added to the sections/chamber slides for
30 min in a humid chamber. For the APAAP technique,
polyclonal primary antibodies (against procollagen I and III)
were incubated with a secondary mouse anti-rabbit anti-
body (Dako) before using the secondary detection
systems.
Double-staining experiments on cryostat sections of the RA
SM were performed by combining the peroxidase technique
with the APAAP technique. The sections were blocked with
20% normal human serum in TBS for 30 min following com-
pletion of peroxidase staining. Isotype-matched mouse
mAbs, rabbit sera, or purified rabbit immunoglobulins at
identical concentrations to the primary antibodies were
used as controls for all immunohistochemical analyses
(Table 3), which gave no positive results. Cross-reactivity of
the peroxidase and the alkaline phosphatase  detection
(theoretically possible on the basis of employing mouse
primary mAbs and anti-mouse secondary antibodies in both
systems) was never observed when using control Ig or
when omitting one or both primary mAbs, presumably
because the peroxidase reaction with diaminobenzidine
eliminates all immunoreactive epitopes from this step.
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Table 2
Clinical characteristics of the patients at the time of synovectomy
Disease
Patients Gender Age duration RF ESR CRP Number of ARA Concomitant
(total) (m/f) (years) (years) (+/–) (mm/h) (mg/l) criteria (RA) medication
Rheumatoid arthritis
16 7/9 61.4 ± 2.2 12.0 ± 2.4 11/4 (n.d. = 1) 33.0 ± 4.6 41.8 ± 7.7 5.2 ± 0.2 MTX (n = 10)
Prednisolone (n = 13)
Sulfasalazine (n = 4)
Gold salts (n = 1)
NSAIDs (n = 12)
Osteoarthritis
21 5/16 70.4 ± 2.6 9.8 ± 3.0 0/8 (n.d. = 13) 15.6 ± 1.9 4.6 ± 1.4 0.3 ± 0.1 MTX (n = 1)
Prednisolone (n = 1)
NSAIDs (n = 11)
None (n = 10)
For the parameters age, disease duration, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) (normal range, < 5 mg/l), and number of
American Rheumatism Association (ARA) criteria (rheumatoid arthritis [RA]), means ± SEM are given; for the remaining parameters, numbers are
provided. m, Male; f, female; RF, rheumatoid factor; +/–, positive/negative; n.d. = not determined; MTX, Methotrexate; NSAIDs, non-steroidal anti-
inflammatory drugs.For comparative immunohistochemical and FACS analy-
ses, the percentage of cells stained for the individual
markers following immunohistochemistry on chamber
slides was determined (total of 100 cells analyzed) and
compared with the percentage of positive cells in FACS
analysis (see later).
Tissue digestion and cell culture
Samples of RA or OA SM were finely minced with scis-
sors (tissue pieces of approximately 30mm3) and
digested for 30 min at 37°C in 20ml PBS containing
0.1% trypsin (Sigma). After removal of trypsin/PBS, the
samples were digested in 20ml 0.1% collagenase P
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Table 3
Antibodies used in the present study
Antibody (technique) Antigen recognized Cellular localization Main cellular expression
MOPC 21 (F/I) – [IgG1 isotype control]
UPC-10 (F/I) – [IgG2a isotype control]
Rabbit Ig/rabbit serum (F/I) – [rabbit Ig control]
Monoclonal
AS02 (F/I) Thy-1 (CD 90) Membrane Fibroblasts, endothelial cells, thymocytes
W6/32 (F) MHC-I (A, B, C) Membrane Ubiquitous
CII 1.47 (F) MHC-II (Pan) Membrane Antigen presenting cells, fibroblasts
SJD1 (F) CD13 Membrane Macrophages, fibroblasts, PMN, T cells
3-2B12 (F/I) Prolyl-4-hydroxylase Cytoplasm Fibroblasts, endothelial cells
V9 (F) Vimentin Cytoplasm Fibroblasts, endothelial cells
4F9 (F/I) von Willebrand factor Cytoplasm Endothelial cells
UCHT-1 (F) CD3 Membrane T cells
TM316 (F) CD11b Membrane Monocytes/macrophages, PMN, NK cells
MoS39 (F/I) CD14 Membrane Monocytes/macrophages
Tyk 4 (F/I) CD14 Membrane Monocytes/macrophages
80H5 (F) CD15 Membrane PMN, monocytes
HD 37 (F) CD19 Membrane B cells
B-Ly 1 (F) CD20 Membrane B cells
Cadherin 5(F/I) CD144 Membrane Endothelial cells
AT 13/5 (F) CD38 Membrane Plasma cells, activated T cells
NKH/1 (F) CD56 Membrane NK cells
PG-M1 (F/I) CD68 Membrane/cytoplasm Macrophages*
HB 15a (F) CD83 Membrane Dendritic cells, activated lymphocytes
BBIG-V1(F/I) VCAM-1 (CD 106) Membrane Fibroblasts, endothelial cells
1.4C3 (F) VCAM-1 (CD 106) Membrane Fibroblasts, endothelial cells
Polyclonal
MP I (F/I) Procollagen I Cytoplasm Fibroblasts
MP III (F/I) Procollagen III Cytoplasm Fibroblasts
Anti-c-Fos(F) c-Fos Nucleus/cytoplasm Ubiquitous
Anti-c-Jun(F) c-Jun Nucleus/cytoplasm Ubiquitous
*The only anti-CD68 monoclonal antibody reported to be specific for macrophages (data not shown) [38]. F, Antibody used for flow cytometry
(FACS) analysis only; F/I, antibody used for FACS and immunohistochemistry; MHC, major histocompatibility complex; VCAM-1, vascular cell
adhesion molecule-1; NK, natural killer.(Boehringer Mannheim) in DMEM/10% FCS for 2h at
37°C, 5% CO2. The cell suspension was then filtered
through a sterile sieve (Sigma), the cells collected by
centrifugation, washed twice with serum-free DMEM
medium, and subsequently cultured for 7 days in
DMEM/10% FCS, 25mM HEPES, 100U/ml penicillin,
100mg/ml streptomycin, and 2.5mg/ml amphotericin B
(all from Gibco BRL, Karlsruhe, Germany). Primary-
culture skin-FB from normal donors (kindly provided by Dr
Sauer, Leipzig, Germany) were prepared by first incubat-
ing skin samples with 0.5U/ml Dispase II (Boehringer
Mannheim) overnight at 4°C and, following removal of the
epidermis, by digesting with 0.25% collagenase P
(Boehringer Mannheim) in DMEM/1% FCS at 37°C and
5% CO2 for 4h. The resulting cell suspension was then
cultured for 14 days as already described. Repeated-
passage HUVEC (kindly provided by Dr C. Syring, Insti-
tute of Clinical Immunology and Transfusion Medicine,
University of Leipzig) were cultured in DMEM/10%
FCS/25mM HEPES containing 10U/ml heparin,
10ng/ml basic fibroblast growth factor (Sigma), and
100mg/ml recombinant endothelial growth factor
(Sigma). The medium was changed every 2–3 days in all
cases. Adherent RA-SFB or OA-SFB were subjected to
very short trypsinization (2 min, 0.25% trypsin/0.2%
EDTA; Gibco), removed from the culture dish by mechan-
ical dislocation, washed in PBS/2% FCS, and used for
negative isolation. The samples were randomly tested to
exclude Mycoplasma contamination.
Negative isolation from primary culture
Trypsinized and washed RA and OA synovial cells from
primary culture (107/ml) were incubated with
4×10 7/ml Dynabeads® M-450 CD14 (clone RMO52;
Dynal) in PBS/2% FCS for 1h at 4°C under bidirec-
tional rotation. Nine milliliters of PBS/2% FCS were
then added and the conjugated cells collected using
the Dynal magnetic particle concentrator®. Magneto-
bead-conjugated cells and unconjugated cells were
collected and washed twice in PBS/2% FCS; cell com-
position and phenotype were analyzed by flow cytome-
try using the antibodies presented in Table 3. For the
purpose of comparison with fourth-passage cells
obtained by conventional isolation (ie repeated passag-
ing; see later), negatively isolated RA-SFB and
OA-SFB were then passaged four times by culture in
complete DMEM/10% FCS (see earlier) with a 1:3
split of confluent cells in each passage.
Conventional isolation of RA-SFB and OA-SFB by
repeated passage
Synovial cells were obtained by trypsin/collagenase diges-
tion of the RA SM as already described. The cells were
subsequently cultured for four passages in DMEM/10%
FCS containing the aforementioned additives by splitting
confluent cells in each passage at a ratio of 1:3.
Flow cytometry
The antibodies presented in Table 3 were used for FACS
analyses of primary-culture RA and OA synovial cells (fol-
lowing 7 days of culture), isolated RA-SFB and OA-SFB
(immediately following isolation or at fourth-passage), con-
ventional fourth-passage RA-SFB and OA-SFB, normal
skin-FB (primary-culture or fourth-passage), or repeated-
passage endothelial cells (HUVEC). Primary antibodies
were used at concentrations of 10–20mg/ml. Standard
single and double-staining procedures for surface mole-
cules were performed as previously described [10]. The
specificity of staining was confirmed using isotype-
matched control mAbs, rabbit serum, or rabbit Ig at identi-
cal concentrations (Table 3). The FACS analysis in
RA-SFB and OA-SFB was not always performed with the
complete set of antibodies due to the initial establishment
of the isolation procedure.
Trypsinized cells were washed twice with serum-free
medium and fixed for 10 min at 4°C in 4% paraformalde-
hyde (Fluka, Deisenhofen, Germany) for detection of
antigens in cytoplasm and/or nucleus (eg prolyl-4-
hydroxylase; Table 3). After washing twice in PBS/2%
FCS, the pellet was resuspended in permeabilization
buffer (PBS/1% FCS, 0.01% NaN3, and 0.5% saponine;
Serva, Heidelberg, Germany) and incubated for 10 min
at room temperature. Unlabeled primary mAbs were
added at saturating concentrations and detected with a
secondary phycoerythrine-labeled goat anti-mouse anti-
body (Dako), both for 45 min at 4°C in permeabilization
buffer. Polyclonal antibodies were incubated with a sec-
ondary mouse anti-rabbit antibody (Dako) before using
the phycoerythrine-labeled goat anti-mouse antibody.
After washing twice in permeabilization buffer, the cells
were incubated for 10 min in PBS/5% FCS and 0.1%
NaN3 without saponine. In the special case of the CD68
epitope recognized by the mAb PG-M1, present on the
cell surface and in the cytoplasm, FACS analysis was
performed in both non-permeabilized and permeabilized
cells. For double-staining analyses, fluoresceine isothio-
cyanate (FITC)-labeled Anti-Thy-1 mAb AS02 (20mg/ml
in PBS/2% FCS) or a matched concentration of the
FITC-labeled IgG1 isotype control mAb were added for
30 min at 4°C.
Analyses were performed on a FACSCAN® using the soft-
ware Cell Quest (Becton Dickinson, San Jose, CA, USA).
Forward and side scatter gates were set to include all
viable cells. In single-staining experiments, a gate was set
to exclude 99% of the cells stained with control Ig. The
gates for control Ig in double-staining experiments were
placed to limit, to less than 1%, not only the individual per-
centages in the upper left, upper right, and lower right
quadrants, but also the sum of the percentages in the
upper left and upper right quadrant, or in the upper right
and lower right quadrant.
Arthritis Research    Vol 3 No 1 Zimmermann et alProliferation assays
The proliferation rates of normal skin-FB as well as OA-SFB
and RA-SFB, derived/negatively isolated from primary
culture, from the fourth passage of the isolated cells (in the
case of OA-SFB and RA-SFB), or from conventional fourth
passage, were assessed by seeding the cells at a density of
1.7×103/well in 96-well plates and subsequent culture in
DMEM/10% FCS with the aforementioned additives for
24h at 37°C and 5% CO2. The cells were then starved in
DMEM/1% FCS for 72h and subsequently stimulated for
18h by addition of 50, 100, or 150U/ml IL-1b (Genzyme,
Rüsselsheim, Germany) or 2.5, 5, or 10U/ml PDGF-BB
(R&D Systems, Wiesbaden, Germany). A total of 1mCi
[3H]-thymidine (Amersham, Braunschweig, Germany) was
added to each well, the cells cultured for an additional 18h,
harvested, and the incorporated radioactivity determined in a
b-counter (Canberra-Packard, Frankfurt/Main, Germany).
Statistical analysis
The data were first subjected to the multi-group Kruskal–
Wallis test because of multiple comparisons. Only those
parameters showing significant differences (P£0.05)
underwent further analysis. The non-parametric Mann–
Whitney U test was then applied for analysis of the pheno-
typic and functional features. The Spearman Rank correla-
tion test was used to analyze correlations among
phenotypic features of SFB and between these features
and the clinical status/treatment of individual patients. Dif-
ferences were considered statistically significant in all
cases for P£0.05. Analyses were performed using the
SPSS 9.0™ program (SPSS Inc., Chicago, IL, USA).
Results
Expression of Thy-1 in RA synovial tissue
The mAb AS02 was tested by immunohistochemistry on
cryostat sections of RA SM to verify the feasibility of this
anti-Thy-1 mAb for positive identification/isolation of SFB.
The mAb AS02 stained connective tissue cells, while largely
sparing the lining layer (see Fig. 3A for details), therefore
reproducing the known distribution of FB within the SM
[21,23,24]. The mAb AS02 showed no overlap with an anti-
CD14 mAb in double-staining experiments, thereby exclud-
ing crossreactivity with monocytes/macrophages (Fig. 3C,E).
However, the mAb AS02 stained endothelial cells, as
demonstrated by double-staining with rabbit Ig against von
Willebrand factor (Fig. 3D,F,G). Cultured, non-stimulated
HUVEC, in contrast, did not express Thy-1 (data not
shown). These results, in line with cytokine induction of
Thy-1 expression on endothelial cells in culture [44–46],
suggest that Thy-1 expression on RA SM endothelial cells
may reflect ongoing inflammation [46].
Phenotype analysis of RA synovial cells in primary
culture
RA synovial cells were subjected to extensive analysis to
carefully characterize the starting population before neg-
ative isolation (ie the 7-day primary culture of synovial
cells resulting from trypsin/collagenase digestion of the
RA SM). The primary culture contained large, spindle-
shaped Thy-1+ SFB (Fig. 1C) and small, round CD14+
cells, most probably macrophages (Fig. 1D; mAb Tyk4),
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Figure 3
Immunohistochemical staining of the RA synovial membrane with the
anti-Thy-1 mAb AS02. (A) This mAb strongly stained cells in the
connective tissue layer beneath the lining layer (APAAP, red staining;
arrows), while largely sparing cells of the lining layer (arrowhead).
Endothelial cells (asterisk) and connective tissue cells in diffuse
infiltrates were also stained, more weakly in the latter case. In serial
sections, the anti-CD14 mAb MoS39 (kindly provided by
Prof GR Burmester, Berlin, Germany) stained macrophages in the
lining layer (arrowhead in (C)) and diffuse inflammatory infiltrates
(peroxidase, brown staining; arrow in (C), (E)); the mAb against von
Willebrand factor stained endothelial cells (peroxidase, brown staining;
(D), (F), (G)). In double-staining experiments, the anti-Thy-1 mAb
AS02 showed no overlap with anti-CD14 staining (E). In contrast,
endothelial cells were double-stained with both the antibody against
von Willebrand factor and the anti-Thy-1 mAb AS02 [arrowheads in
(F); (G)]. There was no positive reaction with control isotype-matched
mAbs (APAAP and peroxidase) (B), employed as controls for double-
staining [(E), (F), (G)]. Original magnification: (A)–(D) and (F), 92 ×;
(E) and (G), 184 ×.as detected by immunohistochemical staining [6,9].
Endothelial cells were absent, as confirmed by lack of
staining for von Willebrand factor (Fig. 1F; mAb 4F9)
and CD144 (Fig. 1G; mAb Cadherin 5), which clearly
identified HUVEC (data not shown). The FB nature of the
spindle-shaped cells was confirmed by intracellular stain-
ing for procollagen I and III (Fig. 1E,H; rabbit antibodies
MP I and MP III). An average of approximately 62% of the
cells stained with the anti-Thy-1 mAb AS02 (n=4 RA
patients; Table 1a and Fig. 4A) in FACS analysis [10].
The average percentage of CD14+ cells was approxi-
mately 15% (n=4; Table 1a and Fig. 4B). There were
<1% T cells (CD3+; mAb UCHT-1), B cells (CD19+/20+;
mAbs HD 37 and B-Ly 1), plasma cells (CD38+; mAb
AT 13/5), NK cells (CD56+; mAb NKH/1), dendritic cells
(CD83+; mAb HB 15a), endothelial cells (CD144+), or
PMN (CD15+; mAb 80H5), indicating that non-adherent
cells had been efficiently removed during primary culture.
Endothelial cells presumably did not adhere to the
culture dish due to the absence of gelatin coating and
unfavorable medium composition (see Materials and
Methods).
Adherent synovial cells were then detached by short-term
trypsinization for 2 min (0.25% trypsin/0.2% EDTA;
Gibco) and used for negative isolation. The total yield of
cells following 7 days of RA primary culture averaged
(5.2±1.1)×107 cells (mean±SEM; n=7; open synovec-
tomy samples). The yield of cells from arthroscopic syn-
ovectomy samples ([3.1±0.6]×107 cells;  n=3) was
comparable. There was no significant difference between
the yield of cells from the RA or OA SM.
Flow cytometry/histochemical analysis of cells nega-
tively isolated from primary culture
Negative isolation from primary culture using Dynabeads®
M-450 CD14 (clone RMO52) resulted in cells that were
Thy-1+ (on average, approximately 74%; n=9; Fig. 2A
and Table 1b) and, more importantly, prolyl-4-
hydroxylase+ (on average, approximately 85%; n=9;
Table 1b) (mAb 3-2B12, Dianova), as shown by FACS
analysis (Table 1b) and confirmed by immunohistochem-
istry in chamber slides. There were very few contaminat-
ing non-specific esterase+ (n = 3 RA and n =3  O A
patients; Fig. 2C), CD14+, CD68+, and/or CD11b+
macrophages (<2%; Fig. 2B,D and Table 1b), as well as
<1% T cells (CD3+), B cells (CD19+/20+), plasma cells
(CD38+), NK cells (CD56+), dendritic cells (CD83+),
PMN (CD15), or endothelial cells (CD144+; von Wille-
brand factor-positive).
The average yield of RA-SFB negatively isolated from
primary culture was (2.8±0.9)×107 cells (mean±SEM;
n=7; open synovectomy samples). A similar yield was
observed upon isolation of cells from arthroscopic syn-
ovectomy samples ([1.7±0.6]×107 cells;  n=3). There
was no significant difference between the yield from the
primary culture of the RA SM and that of the OA SM.
Inclusion of the trypsin component in the initial tissue
digestion led to a considerably higher yield of cells fol-
lowing negative isolation from primary culture (1.2-fold to
5-fold; n=3) than without trypsin or with DNAse instead
of trypsin.
The composition of the cells was very similar to that
obtained with primary-culture or first-passage normal skin-
FB (Table 1g). Comparable results, although with a con-
siderably lower percentage of Thy-1+ cells, were also
obtained when OA-SFB were negatively isolated from
primary culture (Table 1e). Conventional fourth-passage
RA-SFB (Table 1d) or OA-SFB (Table 1f) showed FB
markers on a high percentage of cells (>98%
prolyl-4-hydroxylase+ cells; >80% Thy-1+ cells) and con-
tained virtually no contaminating macrophages (<2%
CD14+-positive or CD68+-positive cells). The same was
true for isolated primary RA-SFB kept in culture until fourth
passage (Table 1c).
Arthritis Research    Vol 3 No 1 Zimmermann et al
Figure 4
FACS analysis of primary-culture RA synovial cells (following 7 days of
culture). The primary culture contained virtually only cells staining either
with the FB-directed anti-Thy-1 mAb AS02 (A) or with the monocyte/
macrophage-specific anti-CD14 mAb Tyk4 (B). 
FITC, fluoresceine isothiocyanate.In vitro morphology of negatively isolated RA-SFB
upon reculture
Negatively isolated RA-SFB showed almost exclusively
spindle-shaped or stellate, flat morphology when recul-
tured (Fig. 5A). Recultured CD14+ cells (Fig. 5B) exhib-
ited small, round morphology with attached Dynabeads®
and contained only very few cells with FB morphology.
Phenotype characterization of negatively isolated
RA-SFB
To verify whether isolated RA-SFB displayed the fea-
tures observed in situ in the RA SM [1,2,12–15,
21–25,28], the expression of several surface or intracel-
lular/nuclear molecules was investigated by FACS analy-
sis (Fig. 6 and Table 4). The phenotype was compared
with that of primary-culture normal skin-FB and isolated
primary-culture OA-SFB (Fig. 6 and Table 4).
Surface antigens
Approximately 74% of RA-SFB expressed the Thy-1
antigen (Fig. 6G and Table 4), compared with 91% of
normal skin-FB (Fig. 6A and Table 4). Approximately
77% of the cells expressed MHC-I molecules, compared
with 90% of normal skin-FB (Table 4). Strikingly, approxi-
mately 66% of the cells expressed MHC-II molecules
(Fig. 6H and Table 4), significantly more than OA-SFB
(17%; Fig. 6E and Table 4) and normal skin-FB (2%;
Fig. 6B and Table 4). At the same time, however, the MFI
for MHC-II did not significantly differ between RA-SFB
and normal skin-FB (Table 4).
The expression of CD13 (aminopeptidase N; EC
3.4.11.2) on 85% of RA-SFB was comparable with that
of normal skin-FB (84%; Table 4).
A low or moderate and variable percentage of normal
skin-FB, as well as OA-SFB and RA-SFB, expressed
VCAM-1 (using two different anti-VCAM-1 mAbs; see
Table 3) without statistically significant differences
among these three different FB preparations (Table 4).
Cytoplasmic antigens
Approximately 85% of the RA-SFB expressed the FB
marker prolyl-4-hydroxylase (Fig. 6M, and Tables 1 and 4),
comparable with the expression in normal skin-FB (71%;
Tables 1 and 4).
RA-SFB showed a similar percentage but a higher MFI for
the cytoskeletal protein vimentin (Fig. 6I) than normal skin-
FB (Fig. 6C and Table 4), although the MFI difference did
not attain statistical significance.
A mean of approximately 45% and 50% of the cells,
respectively (Table 4), expressed procollagen I (Fig. 6J)
and procollagen III (Fig. 6K), as confirmed by double-stain-
ing (Fig. 6L). The percentage of cells expressing procolla-
gen I and III was similar to that of normal skin-FB (68%
and 55%, respectively; Table 4); however, the MFI for pro-
collagen III was significantly higher in RA-SFB (26 versus
15; Table 4).
Cytoplasmic/intranuclear antigens
Approximately 57% of RA-SFB expressed c-Fos (Fig. 6N
and Table 4). Neither the percentage nor the MFI were
significantly different from those of normal skin-FB.
The proto-oncogenes c-Jun and Jun-D (both percentage
of positive cells and MFI) were also comparably expressed
in RA-SFB and normal skin-FB (Fig. 6O and Table 4).
The differences between RA-SFB and normal skin-FB
were, in general, not specific to RA since they were also
observed in the comparison between the disease control
OA-SFB and normal skin-FB (Table 4). In fact, some of the
differences in OA were even more pronounced than in RA,
attaining statistical significance in the direct comparison
between OA and RA (Table 4). Briefly, significantly higher
MFI levels in OA-SFB were noted for MHC-I, MHC-II and
procollagen I, as well as c-Fos. Opposite differences
among the different FB preparations, when considering
the percentage of positive cells or the MFI (eg for the
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Figure 5
Morphology of negatively isolated RA-SFB and macrophages upon
reculture. When recultured, the RA-SFB obtained by negative isolation
with Dynabeads® M-450 CD14 showed almost exclusively spindle-
shaped, flat or stellate morphology (A). Recultured CD14+ cells (B)
exhibited small, round, macrophage-like morphology with attached
magnetobeads, and contained only very few cells with FB morphology.
Original magnification: 368 ×.comparison of MHC-II and procollagen I and III expression
in RA-SFB versus OA-SFB), appeared due to large varia-
tions in one or both parameters.
Comparison of FACS analysis and immunohistochemistry
To verify whether the short-term trypsin digestion (2 min
at 37°C) employed for removal of the cells from the
culture dishes and subsequent FACS analysis altered the
expression of the antigens, selected experiments were
carried out to compare the expression of surface and
intracellular antigens in FACS analysis (Table 1b,e, and
Table 4) and immunohistochemistry on chamber slides.
Negatively isolated SFB from n=3 OA and n=3 RA
patients showed comparable percentages of positive
cells for surface antigens (RA-Thy-1, 95.3% FACS versus
85% immunohistochemistry; CD14, 1.1% versus 0%;
VCAM-1, 0.7% versus 0%) and intracellular antigens
(RA-prolyl-4-hydroxylase, 94.7% versus 85%; CD68,
1.7% versus 0%) with both methods, confirming previ-
ously published results [47] and excluding the possibility
that short-term trypsinization significantly influences
antigen expression.
Phenotype comparison of primary-culture and fourth-
passage RA-SFB
In order to assess differences between the primary
RA-SFB derived from the isolation technique developed in
the present study (immediately following isolation or at
fourth passage) and those obtained by conventional
repeated passaging, the phenotypic features of the three
preparations were compared.
Isolated primary RA-SFB versus conventional fourth-passage
RA-SFB
The percentages of RA-SFB positive for MHC-II, as well
as the MFI for VCAM-1 and c-Jun, were significantly
decreased in conventional fourth passage in comparison
with isolated primary RA-SFB (Fig. 7C,D,K,L and Table 5).
The percentages of cells positive for MHC-I, CD13,
prolyl-4-hydroxylase, vimentin, procollagen I and III, c-Fos
and Jun-D were, in contrast, significantly increased in con-
ventional fourth passage (Fig. 7E–J and Table 5).
The upregulation of the proto-oncogenes c-Fos and
Jun-D was limited to RA, since the percentages of cells
positive for these molecules were significantly decreased
upon passaging in OA-SFB (c-Fos: isolated primary-
culture OA-SFB, 53.9±10.4%; conventional fourth-
passage OA-SFB, 15.0±6.6%; Jun-D: isolated primary-
culture OA-SFB, 37.6±17.7%; conventional fourth-
passage OA-SFB, 25.1±4.2%; n=3 for both SFB
preparations) and numerically decreased upon passaging
in normal skin-FB (c-Fos: primary-culture/first-passage
skin-FB, 87.2±2.1%; conventional fourth-passage skin-
FB, 59.4±26.0%; Jun-D: primary-culture/first-passage
skin-FB, 87.4±1.5%; conventional fourth-passage skin-
FB, 66.2±18.6%; n=3 for both). These decreases were
also noted for the MFI (data not shown). The percentage
of positive cells and/or MFI for c-Fos and Jun-D in con-
ventional fourth-passage RA-SFB were significantly
higher than in OA-SFB as a consequence of these recip-
rocal changes, under these circumstances confirming
previously published data [25].
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Figure 6
Phenotype of isolated primary-culture RA-SFB (lower panels) in
comparison with primary-culture normal skin-FB (upper panel) and
isolated primary-culture OA-SFB (middle panel) (in each case, data
from one representative patient/donor are shown). The double-staining
experiments were performed with the anti-Thy-1 mAb AS02. (A)–(C)
The expression of Thy-1 (A), MHC-II/Thy-1 (B) (double-staining), and
vimentin/Thy-1 (C) (double-staining) in normal skin-FB; (D)–(F) the
expression of Thy-1 (D), MHC-II/Thy-1 (E) (double-staining), and
vimentin/Thy-1 (F) (double-staining) in OA-SFB; (G)–(I) the expression
of the antigens Thy-1 (G), MHC-II/Thy-1 (H) (double-staining),
vimentin/Thy-1 (I) (double-staining) on RA-SFB; (J)–(L) the expression
of the cytoplasmic antigens procollagen I (J) and procollagen III/Thy-1
(K) (single-staining for procollagen III) and (L) (double-staining) in RA-
SFB. Expression of prolyl-4-hydroxylase (M) and the proto-oncogenes
c-Fos (N), and c-Jun (O) in RA-SFB is also shown. See Results and
Table 4 for mean values and statistical comparison among the different
FB types. PE, phycoerythrine; FITC, fluoresceine isothiocyanate.Isolated primary RA-SFB versus isolated fourth-passage
RA-SFB
Some of the differences observed between isolated
primary RA-SFB and conventional fourth passage also
arose when the isolated primary RA-SFB were passaged
until the fourth passage; this applied to the significantly
increased percentage of cells positive for MHC-I,
prolyl-4-hydroxylase, vimentin, and procollagen I and III, as
well as to the decreased percentage of MHC-II-positive
cells (Table 5). In addition, isolated fourth-passage
RA-SFB showed a significantly decreased MFI (but a
numerically increased percentage) for Thy-1 in compari-
son with isolated primary RA-SFB (Table 5).
Conventional fourth-passage RA-SFB versus isolated fourth-
passage RA-SFB
The most important difference between these two prepa-
rations was the significantly increased percentage of cells
positive for the proto-oncogenes c-Fos and Jun-D,
observed only in conventional fourth-passage RA-SFB
(Table 5). The MFI for Thy-1 was also significantly higher
in conventional fourth-passage cells.
Proliferation rates of first- and fourth-passage FB
The proliferation rates of skin-FB and SFB were deter-
mined and the different preparations compared.
Isolated first-passage FB versus conventional fourth-passage
FB
At rest, the proliferation rates of conventional fourth-
passage normal skin-FB did not significantly differ from
those of the corresponding cells in first passage (Fig. 8A).
The same was true for conventional fourth passage
OA-SFB and RA-SFB (Fig. 8B,C). Upon stimulation with
PDGF (2.5 and 5U/ml for all cells, 10U/ml only for
OA-SFB), however, the proliferation rates of skin, RA, and
OA conventional fourth-passage FB were significantly
higher (maximum mean increase, 5.4-fold) than those
observed in first-passage cells (Fig. 8A–C). Following
stimulation with IL-1b, in contrast, only conventional fourth-
passage RA-SFB (150U/ml IL-1b) showed significantly
higher proliferation rates than first-passage cells (Fig. 8C).
Isolated first-passage versus isolated fourth-passage OA-SFB
and RA-SFB
The proliferation rates of isolated fourth-passage cells in
OA-SFB differed significantly from those of isolated first-
passage cells only upon stimulation with IL-1b (50 and
150U/ml; Fig. 8B). Such differences were not observed at
rest or following stimulation with PDGF.
Isolated fourth-passage RA-SFB, in contrast, showed sig-
nificantly higher proliferation rates than first-passage cells
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Table 4
Phenotype of negatively isolated rheumatoid arthritis (RA)-synovial fibroblasts (SFB) in comparison with osteoarthritis (OA)-SFB
and normal skin-FB
skin-FB (n = 8) OA-SFB (n = 9) RA-SFB (n = 9)
Antigen Percent MFI Percent MFI Percent MFI
Thy-1 (CD90; mAb AS02) 91.4 ± 3.0 156 ± 36 62.1 ± 9.0# 120 ± 36 73.8 ± 9.6 109 ± 20
MHC-I 90.2 ± 8.5 414 ± 119 c87.7 ± 6.8 759 ± 170 a77.2 ± 8.1 130 ± 54x
MHC-II 1.5 ± 0.4 225 ± 67 c17.0 ± 7.3# 678 ± 137#a 65.8 ± 12.3# x 223 ± 84x
Aminopeptidase N (CD13) b84.0 ± 10.2 365 ± 163 a83.2 ± 8.7 794 ± 207 84.8 ± 5.9 444 ± 226
VCAM-1 (CD 106) c8.3 ± 3.4 66 ± 33 a28.9 ± 13.2 156 ± 82 c17.5 ± 9.8 122 ± 42
Prolyl-4-hydroxylase 70.7 ± 15.2 101 ± 31 a92.2 ± 2.8 212 ± 44 84.8 ± 2.9 164 ± 45
Vimentin a90.3 ± 4.2 133 ± 34 b94.2 ± 1.7 1083 ± 530 a93.2 ± 1.5 592 ± 290
Procollagen I d68.2 ± 8.3 18 ± 1 d27.5 ± 10.4 39 ± 5#a 44.8 ± 13.0 25 ± 2x
Procollagen III d55.1 ± 9.8 15 ± 2 d22.1 ± 7.8 45 ± 9#a 50.0 ± 14.3 26 ± 3#
c-Fos d87.2 ± 2.1 17 ± 3 d53.9 ± 10.4 35 ± 2#a 57.4 ± 14.0 20 ± 2x
c-Jun d42.7 ± 15.6 13 ± 3 d22.2 ± 10.3 29 ± 3 b42.5 ± 14.0 21 ± 5
Jun-D d87.4 ± 1.5 19 ± 5 d37.6 ± 17.7 33 ± 1#a 53.0 ± 14.8 21 ± 4
Data presented as means ± SEM. MFI, Mean fluorescence intensity; mAb, monoclonal antibody; MHC, major histocompatibility complex; VCAM-1,
vascular adhesion molecule-1. Significant differences among groups are indicated in bold. All cell populations were isolated/obtained from primary
culture (in the case of skin-FB from primary culture or first passage; see Methods for details). # P £ 0.05 Mann–Whitney U test versus skin-FB. 
x P £ 0.05 Mann–Whitney U test versus OA-SFB. a n = 7 Normals, OA or RA patients. b n = 6 Normals, OA or RA patients. c n = 5 Normals, OA or
RA patients. d n = 3 Normals or OA patients.Arthritis Research    Vol 3 No 1 Zimmermann et al
Figure 7
Phenotype comparison of isolated primary-culture (left column) and
conventional fourth-passage RA-SFB (right column) from one
representative patient. Expression of Thy-1 (A, B), MHC-II (C, D),
prolyl-4-hydroxylase (E, F), procollagen III (G, H), c-Fos (I, J), and c-Jun
(K, L). While the percentages of cells positive for MHC-II (C) and the
MFI for c-Jun (K) were significantly higher in isolated primary-culture
RA-SFB, the percentages of cells positive for prolyl-4-hydroxylase (F),
procollagen III (H), and c-Fos (J) were significantly higher in
conventional fourth passage (see Table 5 for details). 
PE, phycoerythrine; FITC, fluoresceine isothiocyanate.
Figure 8
Proliferation rates, as assessed by incorporation of [3H]-thymidine
(counts per minute [cpm]) in: first-passage (white bars) and
conventional (conv.) fourth-passage (dark gray bars) normal skin-FB (n
= 3 each) (A); isolated first-passage (white bars), isolated (isolat.)
fourth-passage (light gray bars), and conventional fourth-passage (dark
gray bars) OA-SFB (n = 3, 3, and 4, respectively) (B); and isolated
first-passage (white bars), isolated (isolat.) fourth-passage (light gray
bars), and conventional fourth-passage (dark gray bars) RA-SFB (n =
4, 3, and 5, respectively) (C), at rest (control) or following stimulation
with IL-1b (50, 100, or 150 U/ml) or PDGF-BB (2.5, 5, or 10 U/ml).
See Results for details. @ P £ 0.05 for the comparison between
cytokine-stimulated FB and non-stimulated control FB within the same
FB preparation. *P £ 0.05 for the comparison between OA-SFB and
RA-SFB.upon stimulation with all concentrations of IL-1b and
PDGF, but not at rest (Fig. 8C).
Conventional fourth-passage versus isolated fourth-passage
OA-SFB and RA-SFB
The proliferation rates of isolated fourth-passage SFB in
both OA and RA were comparable with those of conven-
tional fourth-passage SFB, whether at rest or PDGF-
stimulated (Fig. 8B,C). Stimulation with IL-1b (at all
concentrations), in contrast, induced significantly higher
proliferation in isolated fourth-passage RA-SFB than in
conventional fourth-passage RA-SFB (Fig. 8C). This differ-
ence was specific for RA-SFB, since it was not observed
in OA-SFB (Fig. 8B).
As a consequence of differential IL-1b sensitivity in RA-SFB
and OA-SFB, there were significant differences between
isolated fourth-passage RA-SFB and OA-SFB (P£0.05;
RA>OA, for 100U/ml IL-1b), as well as between conven-
tional fourth-passage RA-SFB and OA-SFB (P£0.05;
OA>RA, for 50 and 150U/ml IL-1b; Fig. 8B,C).
Alternative attempts to isolate RA-SFB
The following isolation techniques were also tested to
compare the quality and reliability of negative isolation
from primary culture with possible alternative methods.
The first technique was positive isolation directly from the
trypsin/collagenase digest using the FB-directed anti-
Thy1/CD90 mAb AS02 and Dynabeads® M-450 goat
anti-mouse IgG. This approach, however, considered
legitimate on the basis of the immunostaining in RA syn-
ovial tissue (Fig. 3A,E), remained unsatisfactory (yield,
only approximately 6% of the initial cell numbers).
Another technique involved negative isolation directly
from the trypsin/collagenase digest. This approach
proved technically prohibitive for the amount of different
anti-leukocyte and anti-endothelial mAbs and Dynabeads®
M-450 goat anti-mouse IgG necessary for complete
removal of all contaminating cell types. Positive isolation
from primary culture with the anti-Thy-1 mAb AS02 and
Dynabeads® M-450 goat anti-mouse IgG was also
tested. This method was unsuitable because: first, the
percentages of contaminating macrophages were too
high/variable (2–15%); second, the isolated SFB showed
a significantly reduced surface density for Thy-1 (MFI 19
versus 152 before isolation; n=4, P£0.05), presumably
due to contact with the mAb used for isolation; third, the
magnetobeads remained attached to the positively iso-
lated SFB for as long as 1 week, thus requiring further
manipulation for their removal (eg with anti-idiotypic
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Table 5
Phenotype of negatively isolated primary-culture rheumatoid arthritis (RA)-synovial fibroblasts (SFB) in comparison with fourth-
passage RA-SFB
Primary-culture Fourth-passage Fourth-passage
RA-SFB RA-SFB RA-SFB
Isolated cells Isolated cells Conventionally passaged cells
(n = 9 patients) (n = 3 patients) (n = 6 patients)
Antigen Percent MFI Percent MFI Percent MFI
Thy-1 (CD90; mAb AS02) 73.8 ± 9.6 109 ± 20 86.6 ± 4.6 41 ± 7# 85.9 ± 4.3 95 ± 17x
MHC-I a77.2 ± 8.1 130 ± 54 99.2 ± 0.2# 117 ± 48 97.4 ± 1.4# 175 ± 78
MHC-II a65.8 ± 12.3 223 ± 84 4.7 ± 2.9# 59 ± 25 4.8 ± 2.4# 80 ± 21
Aminopeptidase N (CD13) 84.8 ± 5.9 444 ± 226 97.2 ± 1.6 108 ± 49 97.9 ± 1.2# 236 ± 95
VCAM-1 (CD106) c17.5 ± 9.8 122 ± 42 n.d. n.d. c0.6 ± 0.1 21 ± 5#
Prolyl-4-hydroxylase 84.8 ± 2.9 164 ± 45 98.7 ± 0.8# 164 ± 62 98.3 ± 0.7# 189 ± 82
Vimentin a93.2 ± 1.5 592 ± 290 99.5 ± 0.4# 717 ± 126 99.7# 325
Procollagen I a44.8 ± 13.0 25 ± 2 92.7 ± 2.8# 25 ± 12 91.0 ± 4.0# 28 ± 5
Procollagen III a50.0 ± 14.3 26 ± 3 94.1 ± 1.8# 21 ± 12 90.2 ± 5.2# 22 ± 4
c-Fos a57.4 ± 14.0 20 ± 2 63.5 ± 16.4 10 ± 5 95.0 ± 0.6#x 17 ± 2
c-Jun b42.5 ± 14.0 21 ± 5 n.d. n.d. d42.1 ± 12.0 9 ± 2#
Jun-D a53.0 ± 14.8 21 ± 4 68.1 ± 13.2 11 ± 5 93.0 ± 1.3#x 18 ± 3
Data presented as means ± SEM. MFI, Mean fluorescence intensity; mAb, monoclonal antibody; MHC, major histocompatibility complex; VCAM-1,
vascular adhesion molecule-1; n.d., not determined. For vimentin expression in conventionally passaged fourth-passage RA-SFB, the median is
shown because of a large deviation from the mean. Significant differences between groups are indicated in bold. # P £ 0.05 Mann–Whitney U test
versus primary-culture RA-SFB. x P £ 0.05 Mann–Whitney U test versus fourth-passage RA-SFB (isolated cells). a n = 7 RA patients. b n = 6 RA
patients. c n = 5 RA patients. d n = 4 RA patients.mAbs); fourth, a substantial proportion of SFB (approxi-
mately 30%) was lost into the negative fraction; and,
finally, a Thy-1-dependent isolation technique bore the
risk of selecting for SFB subpopulations, since the
prolyl-4-hydroxylase+ cells obtained by negative isolation
with Dynabeads® M-450 CD14 contained both a Thy-1+
fraction (RA, 49.3±14.9%, n=6; OA, 43.6±12.0%,
n=4) and a Thy-1– fraction, as demonstrated by double-
staining FACS analysis.
Discussion
Negative isolation from primary culture
Negative isolation of SFB from primary cultures of RA SM
using magnetobead-coupled anti-CD14 mAbs proved
successful, providing satisfactory numbers of cells and
avoiding repeated passaging and numerous cumulative
population doublings. With culture times as short as
7 days, fresh SFB express surface and intracellular anti-
gens typical of the FB lineage and/or SFB features as
reported at a tissue level (Fig. 6 and Table 4) [1,2,12–15,
21–25,28]. This approach may also reduce the risk of in
vitro growth selection. In the case of conventionally iso-
lated RA-SFB, for example, the higher the number of pas-
sages, the higher the percentage of cells with trisomy 7
[33]. Some SFB functions (eg cell density at saturation
and expression of transcription factors), in contrast,
decrease at later passages [5,32,48].
While the use of enzymes for the initial tissue digestion
represents at least a transient stress for the cells, this
method may also represent an alternative to tissue-out-
growth techniques, known to select for premitotic FB [26].
This is important since the relative contribution of pre-
mitotic or postmitotic FB to the pathogenetic features of
RA is presently unclear.
Advantages of negative isolation
Negative isolation with magnetobead-coupled anti-CD14
mAbs shows the following advantages. There is minimal
contamination with macrophages (<2%) and other inflam-
matory cells (all <1%). Thus, although CD14 may be
expressed to a lower degree than CD68 on RA synovial
lining macrophages [36,39], the degree of CD14-positivity
appears more than sufficient to conduct the isolation pro-
cedure. The positive fraction, in turn, contains virtually no
SFB, indicating minimal cell loss, and thereby also exclud-
ing major subset selection. Another advantage is that neg-
ative isolation with Dynabeads® M-450 CD14 avoids
direct contact of SFB with mAbs and/or magnetobeads,
thereby reducing possible functional alterations of the
cells. Finally, the anti-Thy-1 mAb AS02 (used in the paral-
lel attempt to positively isolate SFB) identifies 91% of
normal skin-FB, but not more than 74% of RA-SFB
(Tables 1 and 4). In addition, the prolyl-4-hydroxylase+
cells obtained by negative isolation with Dynabeads®
M-450 CD14 contain both a Thy-1+ and a Thy-1– fraction.
Thy-1-independent isolation thus circumvents the danger
of selecting for Thy-1+ SFB subpopulations, especially rel-
evant since Thy-1+ and Thy-1– FB diverge in several char-
acteristics potentially relevant to RA; for example, cytokine
and matrix production, as well as antigen presentation
[49] (reviewed in [50–52]).
The negative isolation technique, however, also bears pos-
sible disadvantages: the limited number of cells obtained
(approximately 2.8×107), due to the lack of in vitro expan-
sion, and the necessity for reliable access to fresh synovial
specimens. On the other hand, the applicability of this pro-
cedure not only to joint replacement samples, but also to
arthroscopic synovectomy samples, augments the poten-
tial sources of fresh synovial tissue.
Advantages of limited-passage isolation
Limited-passage isolation shows the following advan-
tages. It avoids phenotypic and functional in vitro alter-
ations due to repeated passaging; indeed, even a low
number of passages increases the proliferation rates in
response to cytokine stimulation (Fig. 8). Passaging also
alters the cellular phenotype of RA-SFB, as exemplified
by a strong decrease of the percentage of MHC-II+ cells,
on one hand, and a striking increase of the cells positive
for procollagen I and III, and the proto-oncogenes c-Fos
and Jun-D, on the other (Figs. 7 and 8, and Table 5).
These results are relevant especially in view of the ques-
tion whether proliferation and some phenotypic features
of RA-SFB (in particular, the expression of proto-onco-
genes) can be assimilated to those of dysregulated
growth [1,2]. As these features seem to depend on the
length of in vitro culture, caution should be applied to the
interpretation of data from passaged cells [1,2,12–15,
23–25]. Another advantage is that this isolation proce-
dure reduces the time of exposure to surviving
macrophages to 7 days (in contrast to the weeks typical
of conventional passaging), thus limiting long-term in vitro
changes resulting from monokine secretion or cell–cell
contact between SFB and synovial macrophages.
Limited-passage isolation may therefore allow one to dif-
ferentiate between FB-inherent changes (eg growth
selection and cell senescence) and the changes medi-
ated by the degree or length of contact with surviving
macrophages during the initial passages. A high percent-
age of RA-SFB (and, to a lesser degree, also OA-SFB)
from limited-passage isolation express MHC-II molecules
without in vitro stimulation with cytokines (Table 4), which
in conventionally isolated cells requires stimulation with
interferon-gamma (used not only to explore the antigen-
presentation potential of RA-SFB, but also to inhibit colla-
gen biosynthesis [19,31,53]). In this aspect, the present
in vitro system may be very useful in studies on the inter-
relationship of SFB with T cells or macrophages, in which
the influence of exogenous mediators complicates the
design and/or interpretation of the experiments.
Arthritis Research    Vol 3 No 1 Zimmermann et alSimilarities/discrepancies between the in situ and in
vitro phenotype of RA-SFB
Similarities
The cells obtained by negative isolation generally showed
features similar to those reported in in situ analyses. The
expression of Thy-1, CD13 (aminopeptidase N), and
vimentin exemplify this. The expression of these mole-
cules, particularly their local upregulation by cytokines
[54,55] and/or heterogeneous expression at different
anatomical sites [9,49], may be pathogenetically relevant,
either in terms of defining functionally heterogeneous
SFB subpopulations [49] (reviewed in [50–52]), by pro-
viding pro-inflammatory enzymes [17,47,56–59], or as
targets of autoimmune reactions [60].
MHC-II.  The constitutive MHC-II expression in isolated
RA-SFB and OA-SFB, confirming previous in situ obser-
vations in the RA and OA SM [13,21,22,28] and in sys-
temic scleroderma [61], is probably related to the
inflammatory microenvironment, since normal skin-FB
(Table 4) and normal SFB [31] hardly express MHC-II.
This is further supported by the a strong decrease of the
percentage of MHC-II+ cells upon repeated passage (both
conventional and following negative isolation), possibly
due to lack of or a progressive decrease of external stimu-
lation with pro-inflammatory mediators (Fig. 7 and
Table 5). Notably, there was a significant, negative correla-
tion between the percentage of MHC-II-positive SFB and
treatment of the RA patients with Methotrexate
(r=–0.866,  P=0.01,  n=7), indicating that effective
antirheumatic therapy may be reflected by decreased
MHC-II expression on RA-SFB [28].
Procollagen III.  The significant increase of the MFI for
intracellular procollagen III in RA-SFB and OA-SFB
(Table 4) suggests that the pattern of SFB activation may
be functional (among other things) to the increase of colla-
gen metabolism; this is supported by the increased
expression of collagen a2I and a1III mRNA in the RA SM
in situ [2,23,24], in comparison with normal or non-RA
synovial tissue. Also, in as much as procollagen III is the
fetal form of collagen used in wound healing and tissue
repair (reviewed in [62,63]), ongoing fibrosis may be a
considerable component of the disease process in RA
(and OA), in analogy to systemic scleroderma [61] or
interstitial kidney fibrosis [11,26]. A striking increase of
procollagen I and III expression in RA-SFB from primary
culture to fourth passage (increase of positive cells by
³38%; Fig. 7 and Table 5), on the other hand, indicates
that primary-culture cells do not exploit their full potential
of matrix production.
Discrepancies
The expression of VCAM-1 [1,15,64,65] and Jun and Fos
proto-oncogenes [23,25,66,67] showed some in situ/in
vitro discrepancies.
VCAM-1. Surprisingly, only a moderate and variable per-
centage of RA-SFB (whether conventionally passaged or
negatively isolated from primary culture) expressed the
adhesion molecule VCAM-1 (Tables 4 and 5). There were
also no significant differences between RA-SFB and
OA-SFB or normal skin-FB (Table 4). This is in apparent
contrast to the enhanced expression of VCAM-1 reported
in the lining layer of RA and OA synovial tissue [64,65];
however, it is well compatible with the large variability in
VCAM-1 expression observed in vitro (Table 4) [1,15,68]
and  in situ [1,15]. The significant, positive correlation
between VCAM-1 expression in isolated primary-culture
RA-SFB and the erythrocyte sedimentation rate in RA
patients (r=1.00, P=0.000, n=4) indicates that the vari-
ability may depend on disease activity, as also suggested
in recent reports [68–70].
Proto-oncogene expression. Negatively isolated RA-SFB
expressed c-Fos, c-Jun, and Jun-D (Table 4), in analogy to
the features of SFB in RA SM [23,25,66]. The expression
of c-Jun and Jun-D in the present study could be unequiv-
ocally demonstrated by FACS analysis (Table 4), while
previous immunohistochemical studies had failed to
detect these molecules in situ [23]. Notably, however, the
degree of proto-oncogene expression (both percentage of
positive cells and MFI) did not significantly differ from that
of normal skin-FB (Fig. 6 and Table 4) or, as previously
reported, of SFB from traumatic joint injury [67]. This
finding supports in situ observations that, at a single-cell
level, the degree of proto-oncogene expression in RA, OA,
and joint trauma is similar [23], thereby questioning
whether proto-oncogene expression in RA reflects per se
cell transformation and/or severe metabolic abnormalities.
Notably, the expression of the proto-oncogenes c-Fos and
Jun-D was strikingly increased in conventional fourth-
passage RA-SFB as compared with isolated primary-culture
RA-SFB (increase of positive cells ³38%; Fig. 7 and
Table 5). This increase was limited to RA, since the percent-
age of cells positive for these molecules was significantly
decreased in OA-SFB and numerically decreased in normal
skin-FB upon passaging. As a consequence of these recip-
rocal changes, the percentage of positive cells and/or MFI
for c-Fos and Jun-D in conventional fourth-passage RA-SFB
was significantly higher than in OA-SFB, under these cir-
cumstances confirming previously published data [25].
Finally, a significant, positive correlation between the per-
centage of c-fos+ and procollagen I and III+ isolated
primary-culture SFB in both RA and OA patients (RA:
c-fos/procollagen I,  r=1.000,  P=0.00,  n=7;  c-fos/pro-
collagen III,  r=0.964,  P=0.00,  n=7) suggests a link
between  c-fos expression and augmented matrix produc-
tion by SFB in rheumatic disorders, in line with the known
regulation of collagen expression by the activator protein-1
transcription factor (reviewed in [13]).
Available online http://arthritis-research.com/content/3/1/072
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
hSuitability of fibroblast markers for unequivocal
identification of SFB
None of the markers used to recognize SFB [9,23,24,62]
proved to be universal (Table 4) or stable upon passaging
(Fig. 7 and Table 5). Cellular uridine diphosphoglucose
dehydrogenase activity, a useful histochemical marker for
intimal SFB [37], while clearly detectable by immunohis-
tochemistry in the lining layer of RA SM tissue sections,
was also only positive in a small subpopulation of cul-
tured SFB (90% negative, 9% weakly positive, 1%
strongly positive). Thus, despite its parallel recognition of
endothelial cells [62], prolyl-4-hydroxylase at present
remains the most suitable FB marker (see Tables 1, 4
and 5).
The variable degree of positivity for different markers
observed in the present study supports the existence of
different SFB subpopulations or maturational stages
(Tables 4 and 5, and Fig. 6E,H,I) [1,15]. By providing iso-
lated SFB that do not undergo major subset selection, the
present technique may allow, on one hand, the further
characterization of these subpopulations and, on the
other, the identification of more universal and/or less regu-
lated pan-FB markers.
In summary, the present technique allows the isolation of
highly enriched SFB with very limited in vitro culture time.
These cells clearly show different phenotypic and func-
tional properties in comparison with conventional fourth-
passage RA-SFB. In conjunction with simultaneously
derived synovial macrophages from the same patient (eg
the positive fraction of the CD14 negative isolation), nor-
mally lost upon repeated passage due to their inability to
divide in vitro (reviewed in [1]), and non-adherent, viable
cells from the supernatant of the primary culture, recre-
ation of a simplified ‘rheumatoid’ system can be attempted
to investigate the relative contribution of the different cells
to joint pathology [18,71].
Note added in proof
Increased levels of c-Fos protein in late-passage versus
early-passage RA-SFB, but decreased levels of c-Fos in
late-passage OA-SFB, ie an RA-specific increase of c-Fos
transcription/translation in late-passage SFB, has recently
been confirmed by Shimizu et al [72].
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